Literature DB >> 30648775

Intravoxel Incoherent Motion Combined With Dynamic Contrast-Enhanced Perfusion MRI of Early Cervical Carcinoma: Correlations Between Multimodal Parameters and HIF-1α Expression.

Xiangsheng Li1, Shandong Wu2, Dechang Li3, Tao Yu4, Hongxian Zhu1, Yunlong Song1, Limin Meng1, Hongxia Fan1, Lizhi Xie5.   

Abstract

BACKGROUND: The identification of hypoxia inducible factor (HIF-1α) expression is helpful for the quantitative assessment of tumor hypoxia. The application of multimodal imaging techniques may play a part in the assessment of HIF-1α expression of cervical carcinoma.
PURPOSE: To investigate the correlations between multiple imaging parameters and HIF-1α expression of early cervical carcinoma and to determine whether tumor hypoxia can be predicted using multisequence imaging parameters. STUDY TYPE: Prospective observational. POPULATION: One hundred patients with early cervical carcinoma. FIELD STRENGTH/SEQUENCES: 3.0 T MRI including intravoxel incoherent motion (IVIM) diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) perfusion MRI sequences. ASSESSMENT: DCE-MRI and IVIM DWI were performed for all patients. The imaging parameters included volume transfer constant (Ktrans ), rate constant (Kep ), extravascular extracellular volume fraction (Ve ), D, D*, and f. STATISTICAL TESTS: The comparisons of imaging parameters between two independent groups were performed using the Mann-Whitney U-test. Multiple linear regression analysis was performed to determine the correlation between multiple imaging parameters and HIF-1α expression. The diagnostic ability of DCE-MRI, IVIM DWI, and the combination of two techniques for discriminating high-expression and low-expression groups were analyzed.
RESULTS: The high-expression group had a lower Ktrans or Kep value than the low-expression group (P = 0.03; 0.02), while the high-expression group had a higher Ve value than the low-expression group (P = 0.03). The high-expression group had a higher D or f value than the low-expression group (P = 0.02; 0.02). Ktrans , Kep , D, Ve , and f values were independently correlated with HIF-1α expression. The sensitivity or accuracy of a combined method was higher than that of DCE-MRI or IVIM DWI individually (P = 0.03, 0.02; 0.04, 0.03). DATA
CONCLUSION: The combination of DCE-MRI and IVIM DWI can improve the diagnostic ability of discriminating different HIF-1α expression levels for early cervical tumors. LEVEL OF EVIDENCE: 1 Technical Efficacy Stage: 2 J. Magn. Reson. Imaging 2019;50:918-929.
© 2019 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  cervical carcinoma; diffusion-weighted imaging; dynamic contrast-enhanced; hypoxia inducible factor; intravoxel incoherent motion; magnetic resonance imaging

Year:  2019        PMID: 30648775     DOI: 10.1002/jmri.26604

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  4 in total

1.  Evaluation of HIF-1α Expression in a Rat Glioma Model Using Intravoxel Incoherent Motion and R2* Mapping.

Authors:  Dongdong Wang; Yiping Lu; Xuanxuan Li; Nan Mei; Pu-Yeh Wu; Daoying Geng; Hao Wu; Bo Yin
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

2.  Effect of multidisciplinary collaborative continuous nursing on the psychological state and quality of life of patients with cervical cancer.

Authors:  Dongfang Han; Dajun Wang; Jia Yang; Xiaomei Li
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

3.  Soft tissue sarcoma: correlation of dynamic contrast-enhanced magnetic resonance imaging features with HIF-1α expression and patient outcomes.

Authors:  Xiangwen Li; Yuxue Xie; Hongyue Tao; Shuang Chen; Yiwen Hu; Rong Lu; Qing Li; Bo Xiong
Journal:  Quant Imaging Med Surg       Date:  2022-10

Review 4.  Perfusion-driven Intravoxel Incoherent Motion (IVIM) MRI in Oncology: Applications, Challenges, and Future Trends.

Authors:  Mami Iima
Journal:  Magn Reson Med Sci       Date:  2020-06-15       Impact factor: 2.471

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.